Clinical Study of GT201 in Combination with PD-1 Inhibitor for Advanced Head and Neck Tumors

Inclusion Criteria:

1. Voluntarily join the study, signed informed consent form,, willing and able tocomply with the study protocol;

2. Age 18 to 70 years old;

3. Diagnosis with recurrent or metastatic head and neck malignant tumors andreceived≤2 lines of systemic therapy;

4. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1;

5. Expected survival time of ≥ 12 weeks;

6. Good function of vital organs;

7. Subjects who enter this study due to poor treatment efficacy or intolerancemust have medical records describing their condition after previous treatmentor imaging records of lesion evaluation before tumor sampling;

8. At least one measurable target lesion that meets the definition of RECIST v1.1after tumor sampling.

Exclusion Criteria:

• 1.Patients with uncontrollable tumor-related pain as judged by the investigator;participants requiring analgesic medication must already have a stable analgesicregimen at the time of study entry; symptomatic lesions suitable for palliativeradiotherapy should be completed prior to study entry;

• 2.Known mental illness, alcoholism, drug use or substance abuse;

• 3.Pregnant or lactating women; or women who are pregnant, breastfeeding, or planningto become pregnant within 1 year after cell infusion;

• 4.Those who have received other clinical trial drug treatment within 4 weeks beforeNMA-LD chemotherapy or plan to participate in other clinical trial drug treatmentduring the study;

• 5.The investigators determine that other conditions that make the patient notsuitable for enrollment.